9 results about "Dinitrophenyl" patented technology

The invention relates to the technical field of preparation of N-(2, 4-dinitrophenyl)-4-nitrobenzoyl aniline, in particular to a method for preparing a nitro amide compound by adopting a microreactor. The method for preparing the nitro amide compound comprises the following steps: introducing a sulfuric acid solution of 4-nitro-N-phenylbenzamide and a nitric acid aqueous solution into a microreactor, and reacting to obtain N-(2, 4-dinitrophenyl)-4-nitrobenzamide; the microreactor is provided with at least two reaction modules which are connected in series, and a sulfuric acid solution of 4-nitro-N-phenylbenzamide is divided into at least two strands which are respectively fed into a first reaction module of the microreactor and other reaction modules except the first reaction module; and the nitric acid aqueous solution enters the microreactor in a way of at least one stream. According to the method, the microreactor is used as a reaction carrier, the temperature in the reaction process is controllable, the raw material conversion rate is increased, and the residual amount of an intermediate N-4-nitro-(4-nitrophenyl) benzamide is reduced.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

This invention relates to the field of organic synthesis technology, specifically disclosing a method for preparing N-(2,4-diaminophenyl)-4-aminobenzamide. The method involves using N-(2,4-dinitrophenyl)-4-nitrobenzamide as a raw material, adding a catalyst, buffer salt, and water, mixing the mixture, and then purging with nitrogen gas to maintain pressure. The nitrogen gas is then replaced with hydrogen gas, and a hydrogenation reaction is carried out under a hydrogen atmosphere. After the reaction is complete, an acid is added to quench the reaction, the catalyst is removed by filtration, and then an alkali is added to adjust the pH to above 8. The mixture is then filtered to obtain crude N-(2,4-diaminophenyl)-4-aminobenzamide. The crude product is purified by recrystallization and finally dried to obtain N-(2,4-diaminophenyl)-4-aminobenzamide. The method provided by this invention has high selectivity, few side reactions, protects the amide bond from hydrolysis, and produces a product with high purity.

The present invention provides novel 2, 4-dinitrophenol (DNP) derivatives and prodrugs thereof as modulators of mitochondrial function. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of their use in the treatment of various diseases and conditions associated or associated with mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart failure or renal failure, neurodegenerative disease, or aging-related disease).

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block.In particular, the at least one protein-based building block comprised in the molecule of the technology:a) comprises at least one conjugation site or attachment point;b) has a molecular mass of 2.5 to 70 kDa;c) has a globular three-dimensional (3D) structure;d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; ande) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5×10−4 mol / litre·ft

This invention relates to the field of N-(2,4-dinitrophenyl)-4-nitrobenzamide preparation technology, specifically to a green method for preparing nitramide compounds. The method involves adding a catalyst and dispersant to a reactor and mixing them uniformly. Then, a first and a second stream of materials are simultaneously added dropwise to the reactor for reaction. The temperature within the system is controlled during the dropwise addition. After the dropwise addition is complete, the temperature is increased to continue the reaction. After the reaction is completed, N-(2,4-dinitrophenyl)-4-nitrobenzamide is obtained through post-treatment. The first stream is a dispersion containing 4-nitro-N-phenylbenzamide, and the second stream is a nitrating agent consisting of a uniform mixture of N₂O₅ and nitric acid. This preparation method features high product conversion rate, a mild reaction process, safe and controllable production process, effectively reduces the amount of residual intermediates, and minimizes pollution.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.